19
3
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T22349 | JNJ-38158471 | CS-2660 | VEGFR , c-RET , c-Kit |
JNJ-38158471 (CS-2660), a highly selective, orally available, well tolerated VEGFR2 inhibitor with IC50 of 40 nM, inhibits closely related tyrosine kinases such as Ret and Kit with IC50 of 180 nM and 500 nM. | |||
T2516 | Amuvatinib | MP470,HPK 56 | Apoptosis , FLT , c-Met/HGFR , c-RET , DNA/RNA Synthesis , PDGFR , c-Kit |
Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity. | |||
T0520 | Lenvatinib | E7080 | VEGFR , FGFR , c-RET , PDGFR , c-Kit |
Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (... | |||
T4053 | AST 487 | NVP-AST 487 | VEGFR , FLT , c-RET , Bcr-Abl , c-Kit |
AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3. | |||
T8541 | Lenvatinib mesylate | E7080 (mesylate) | VEGFR , FGFR , c-RET , PDGFR , c-Kit |
Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities. | |||
T1792 | Regorafenib | BAY 73-4506,Fluoro-Sorafenib | Raf , VEGFR , c-RET , PDGFR , c-Kit , Autophagy |
Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ and is orally active. Regorafenib has antitumor and anti-angiogenic activity. | |||
T6028 | PF 477736 | PF 00477736,PF-477736,PF-736,PF-00477736,PF477736 | c-Fms , VEGFR , FGFR , FLT , c-RET , Chk , CDK , Src , Aurora Kinase |
PF 477736 (PF-736,PF-00477736) is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CSF1R), Ret and Yes. | |||
T11638 | Ilorasertib hydrochloride | ABT-348 hydrochloride | Aurora Kinase |
Ilorasertib hydrochloride (ABT-348 hydrochloride) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora C, Aurora B, and Aurora A (IC50s: 1 nM, 7 nM, 120 nM). It also suppresses RET tyrosine kinase,... | |||
TQ0059 | Ilorasertib | ABT-348 | VEGFR , FLT , c-RET , PDGFR , Aurora Kinase |
Ilorasertib (ABT-348) (ABT-348) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora A/Aurora B/Aurora C (IC50s: 120 nM/7 nM/1 nM). It also suppresses RET tyrosine kinase, PDGFRβ, and Flt1 (IC50s: ... | |||
T1792L | Regorafenib monohydrate | Raf , VEGFR , c-RET , PDGFR , c-Kit , Autophagy | |
Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, KIT, RET, RAF-1, B-RAF and B-RAF(V600E) respect... | |||
T27715 | KBP-7018 | KBP 7018 | |
KBP-7018 is a potent, selective tyrosine kinase inhibitor with effects on three fibrotic kinases c-KIT, RET, and PDGFR (IC50 values are 10nM, 7.6 nM and 25nM respectively). | |||
T70382 | KBP-7018 HCl | ||
KBP-7018 Hydrochloride is a novel, tyrosine kinase-selective inhibitor with potent effects on three fibrotic kinases (c-KIT, PDGFR, and RET). | |||
T14282 | Amuvatinib hydrochloride | HPK 56 hydrochloride,MP470 hydrochloride | Others |
Amuvatinib hydrochloride (MP470 hydrochloride) is an orally administred multi-targeted tyrosine kinase inhibitor that exhibits strong efficacy against mutant forms of c-Kit, PDGFRα, Flt3, c-Met, and c-Ret, while also act... | |||
T14363 | AZ-23 | AZ 23,AZ23 | Trk receptor |
AZ-23 is an inhibitor of ATP-competitive and Trk kinase A/B/C. For TrkA, TrkB, FGFR1, Flt3, Ret, MuSk, Lck, the IC50s values are 2 nM, 8 nM, 24 nM, 52 nM, 55 nM, 84 nM, 99 nM, respectively. | |||
T10157 | Regorafénib N-oxyde (M2) | Raf , VEGFR , c-RET , PDGFR , c-Kit , Drug Metabolite | |
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1 (IC50s: 13/4.2/46, 1.5, 22, 7, and 2.5 nM). | |||
T2070 | Agerafenib | RXDX-105,CEP 32496,CEP-32496,CEP32496 | Raf , c-RET , Bcr-Abl , PDGFR , Src , c-Kit |
Agerafenib (CEP32496) is a highly potent inhibitor of BRAF. | |||
T73033 | TRK II-IN-1 | Trk receptor | |
TRK II-IN-1 is a potent type II inhibitor of tropomyosin receptor kinases (TRK), demonstrating inhibitory half-maximal inhibitory concentrations (IC50s) of 3.3, 6.4, 4.3, and 9.4 nM against TRKA, TRKB, TRKC, and the muta... | |||
T37582 | Ganglioside GM1 Mixture (ovine) (ammonium salt) | ||
Ganglioside GM1is a monosialylated ganglioside and the prototypic ganglioside for those containing one sialic acid residue.1,2It is found in a large variety of cells, including immune cells and neurons, and is enriched i... | |||
T14928 | Agerafenib hydrochloride | RXDX-105 hydrochloride,CEP-32496 (hydrochloride) | c-RET , c-Kit |
Agerafenib hydrochloride is a highly potent inhibitor of BRAFV600E (Kd: 14 nM). |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-01456 | HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-pr... | |||
TMPK-01451 | HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-pr... | |||
TMPK-01450 | HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-pr... |